Claims for Patent: 11,826,397

Summary for Patent: 11,826,397

Title:	Method of treating prostate cancer with GnRH antagonist
Abstract:	The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Inventor(s):	Egbert A. van der MEULEN, Laszlo Balazs Tanko
Assignee:	Ferring BV
Application Number:	US17/710,899
Patent Claims:	1. A method of treating a patient with prostate cancer, comprising: selecting a patient with prostate cancer and a history of at least one cardiovascular event; administering to the patient with prostate cancer and a history of at least one cardiovascular event an initial dose of degarelix of 240 mg given as two subcutaneous injections of 120 mg each at a concentration of 40 mg/mL, and administering to the patient a maintenance dose of degarelix of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL, wherein the maintenance dose is administered approximately every 28 days after the previous dose of degarelix for a duration treatment, wherein the patient's risk of developing or experiencing an additional cardiovascular event is diminished compared to a risk of developing or experiencing an additional cardiovascular event upon treatment with a GnRH agonist, wherein the at least one cardiovascular event is one or more selected from myocardial infarction, ischemic heart disease, ischemic stroke, hemorrhagic stroke, and other arterial thrombotic/embolic events. 2. The method of claim 1, wherein the patient has one or more risk factors selected from greater than 65 years of age, high alcohol consumption, abstinence from alcohol, high blood pressure, low baseline serum testosterone, and prostate cancer disease state. 3. The method of claim 1, wherein the patient has one or more risk factors selected from greater than 65 years of age, abstinence from alcohol, high blood pressure, and low baseline serum testosterone. 4. The method of claim 3, wherein the patient has high blood pressure that is greater than or equal to 130 over 85 mm Hg. 5. The method of claim 1, wherein the patient's prostate cancer is at a stage selected from localized prostate cancer, locally advanced prostate cancer, metastatic prostate cancer, and non-classifiable prostate cancer. 6. The method of claim 1, wherein the patient has locally advanced prostate cancer. 7. The method of claim 1, wherein the patient has metastatic prostate cancer. 8. The method of claim 1, wherein the at least one cardiovascular event is one or more selected from myocardial infarction and ischemic stroke. 9. The method of claim 1, wherein the treatment with a GnRH agonist is treatment with monthly intramuscular injections of 7.5 mg leuprolide. 10. The method of claim 1, wherein the subject's risk of experiencing an increase in body weight is diminished compared to a risk of experiencing an increase in body weight upon treatment with a GnRH agonist. 11. The method of claim 10, wherein the treatment with a GnRH agonist is treatment with monthly intramuscular injections of 7.5 mg leuprolide.